Status:
COMPLETED
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
Lead Sponsor:
GlaxoSmithKline
Conditions:
Postoperative Nausea and Vomiting
Nausea and Vomiting, Postoperative
Eligibility:
FEMALE
18-55 years
Phase:
PHASE2
Brief Summary
This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
Detailed Description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antago...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Females age 18-55
- Laparoscopic/laparotomic gynecological procedure of laparoscopic gallbladder removal
- Exclusion criteria:
- Pregnant or breastfeeding
- Post-menopausal
- Not undergoing general anesthesia
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
701 Patients enrolled
Trial Details
Trial ID
NCT00108095
Start Date
October 1 2004
End Date
August 1 2005
Last Update
January 20 2017
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Montgomery, Alabama, United States, 36106
2
GSK Investigational Site
Phoenix, Arizona, United States, 85032
3
GSK Investigational Site
Arcadia, California, United States, 91007
4
GSK Investigational Site
Duarte, California, United States, 91010